ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

ACON Laboratories Announces Breakthrough 4-in-1 Flowflex® Plus RSV + Flu A/B + COVID Home Test





Single-Swab Solution: New Over-the-Counter Test Simultaneously Detects and Differentiates RSV, Flu A/B, and COVID from the Comfort of Home

SAN DIEGO, CA, October 28, 2025 /24-7PressRelease/ -- ACON Laboratories, Inc., a leading global medical device manufacturer, announced today that its Flowflex® Plus RSV + Flu A/B + COVID Home Test has received 510(k) clearance from the U.S. Food & Drug Administration (FDA). The Flowflex Plus RSV + Flu A/B + COVID Home Test (K251749) is an over-the-counter (OTC) rapid antigen test that can be administered in the comfort and privacy of consumers' homes. This new test will be manufactured domestically in ACON's state-of-the-art facility in San Diego, CA.

The Flowflex Plus RSV + Flu A/B + COVID Home Test is a lateral flow immunoassay intended for the rapid, simultaneous qualitative detection and differentiation of respiratory syncytial virus (RSV), influenza A, influenza B (Flu A/B), and SARS-CoV-2 (COVID) protein antigens. This test is authorized for non-prescription home use with self-collected anterior nares nasal swab specimens. This is not only the first device of its kind with four analytes in one test (4-in-1), and the first RSV home test, but it is also the first respiratory home test to earn FDA clearance for children aged 6-23 months when administered by an adult using ACON's proprietary nasal swab guard.

In summary, this innovative product is:
- The first FDA-cleared 4-in-1 respiratory home test
- The first FDA-cleared RSV home test
- The first FDA-cleared respiratory infection home test for children aged 6-23 months

"We are excited to introduce this game-changing 4-in-1 home test. This product further demonstrates our commitment to enabling consumers to take charge of their own health. Symptoms of respiratory infections can be similar, so knowing which infection you have is important for making early treatment decisions, which can lead to better outcomes. We expect the Flowflex 4-in-1 home test will bring peace of mind to parents of young children as well as the elderly, the immune-compromised, and those of us who are in contact with at-risk populations," commented VP of Sales & Marketing, Michael Lynch.

Flowflex continues to be America's #1 home test brand¹, and the Flowflex Plus RSV + Flu A/B + COVID Home Test will be widely available at major retailers later this year. A list of authorized distributors and retail partners can be found at www.flowflexcovid.com.

¹ SOURCE: Circana Retail Sales Data (Units sold)

---
Press release service and press release distribution provided by https://www.24-7pressrelease.com

Recent Quotes

View More
Symbol Price Change (%)
AMZN  230.30
+1.05 (0.46%)
AAPL  269.70
+0.70 (0.26%)
AMD  264.33
+6.32 (2.45%)
BAC  52.58
-0.29 (-0.55%)
GOOG  275.17
+6.74 (2.51%)
META  751.67
+0.23 (0.03%)
MSFT  541.55
-0.52 (-0.10%)
NVDA  207.04
+6.01 (2.99%)
ORCL  275.30
-5.53 (-1.97%)
TSLA  461.51
+0.96 (0.21%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.